<DOC>
	<DOCNO>NCT00999531</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability repeat dose GS-9411 healthy volunteer . GS-9411 sodium channel inhibitor , may restore airway hydration mucociliary clearance lung .</brief_summary>
	<brief_title>A Randomized , Double-Blind , Placebo-Controlled Multiple Dose Trial GS-9411 Healthy Volunteers</brief_title>
	<detailed_description>GS-9411 evaluate potential therapy improve airway hydration mucociliary clearance patient cystic fibrosis . This study evaluate safety tolerability 3 dose level GS-9411 inhale product , compare match placebo , administer twice daily 14 day .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Males female , 18 65 year age No clinically important abnormal physical finding Screening No clinically relevant abnormality result laboratory evaluation Screening Must test negative hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) , human immunodeficiency virus ( HIV ) Screening Normal electrocardiogram ( ECG ) Screening Normal blood pressure ( BP ) heart rate ( HR ) absence medication body weight 50 125 kg within ± 15 % ideal body weight body mass index ( BMI ) 18 28 kg/m2 Screening Able communicate well investigator comply requirement entire study Provision write informed consent participate show signature volunteer consent form Nonsmokers least 180 day ( 6 month ) duration ( &lt; 10 pack/year history ) prior Screening Negative drug abuse ( include alcohol ) Screening Day 5 Must willing abstain alcohol strenuous exercise 48 hour prior Day 5 study Forced expiratory volume 1 second ( FEV1 ) ≥ 80 % predict normal age , gender , height Screening predose Normal intraocular pressure ( IOP ) 10 21 mm Hg Screening Male subject sexually active must willing use effective barrier contraception ( e.g. , condom ) heterosexual intercourse Day 5 completion study continue least 90 day date last dose study drug Male subject must refrain sperm donation Day 5 completion study continue least 90 day date last dose study drug Nonlactating female . Females hormone replacement therapy ( estrogen/progesterone ) contraceptive therapy must stabilize product dose least 90 day prior Screening Females must negative serum gonadotropin pregnancy test Screening Day 1 Nonpregnant female childbearing potential must agree use highly effective ( &lt; 1 % failure rate ) contraception heterosexual intercourse Screening , throughout study , least 30 day follow last dose study drug Any prior exposure GS9411 Administration investigational drug period 84 day ( 12 week ) prior Screening ; 112 day ( 16 week ) previous investigational drug new chemical entity A need medication period 0 5 day prior Screening , except deem principal investigator/clinical investigator interfere outcome study Existence surgical medical condition , judgment clinical investigator , might interfere absorption , distribution , metabolism , excretion drug Presence history allergy require treatment . Hay fever allow unless active require treatment within 56 day ( 8 week ) Screening Donation loss great 400 mL blood period 84 day ( 12 week ) prior Screening Serious adverse reaction hypersensitivity drug Presence history pulmonary disease ( e.g. , asthma , emphysema , chronic bronchitis , CF , bronchiectasis ) Lactating female History glaucoma Consumption drug and/or herbal preparation capable induce hepatic enzyme metabolism ( e.g. , barbiturate , rifampicin , carbamazepine , phenytoin , primidone , St. John 's Wort ) enzymeinhibiting agent ( e.g. , cimetidine ) similar drug within 28 day ( 5 halflives inducing/inhibiting agent , whichever long ) Screening Major surgery within 180 day ( 6 month ) start study Subjects experience significant upper low respiratory tract infection within 42 day ( 6 week ) prior Screening Subjects significant history respiratory , renal , hepatic , cardiovascular ( include history systemic hypertension require therapy ) , metabolic , neurological , hematological , gastrointestinal , cerebrovascular , significant medical illness disorder , judgment investigator , may interfere study require treatment may affect evaluation safety study drug Subjects elevate liver enzyme concentration Screening Day 1 Hemoglobin level &lt; 130 g/L take Screening Day 1 Serum potassium &gt; 5 mEq/L take Screening Day 1 Poor venous access</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Cystic Fibrosis</keyword>
	<keyword>CF</keyword>
	<keyword>Mucociliary Clearance</keyword>
	<keyword>Epithelial Sodium Channel Inhibitor</keyword>
	<keyword>ENaC Inhibitor</keyword>
	<keyword>Airway Hydration</keyword>
	<keyword>Amiloride</keyword>
</DOC>